Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup W-135
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB10061 | Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | A conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. |
| DB13887 | Meningococcal polysaccharide vaccine group W-135 | Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and... |
| DB15680 | Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen | This antigen is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. It is approved for use in individuals 10... |
| DB10801 | Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen | Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis serogroup W-135. The vaccine... |
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|